Semaglutide & Peripheral Artery Disease: Response to STRIDE Trial Results

Researchers have acknowledged observations regarding the STRIDE trial, which investigated semaglutide treatment for patients experiencing symptomatic peripheral artery disease. The acknowledgment came in response to correspondence from Teba Alnima and Mark M Smits concerning the trial’s findings.

The STRIDE trial (NCT04560998) demonstrated that once-weekly subcutaneous semaglutide, at a 1.0 mg dosage, led to significant improvements in walking capacity, symptom management, and overall quality of life for individuals diagnosed with symptomatic peripheral artery disease and type 2 diabetes, according to findings published in Diabetes Care.

Mark M Smits, affiliated with the Radboud University Medical Center in Nijmegen, Netherlands, has disclosed research funding and consulting fees from Novo Nordisk, as well as lecture payments from Eli Lilly, with all financial benefits directed to his institution. Teba Alnima, also of Radboud University Medical Center, reported no competing interests.

The initial correspondence prompting this response focused on the results of the STRIDE trial and its implications for treating peripheral artery disease. Details of the original observations by Alnima and Smits have not been publicly released.